Leaderboards/Multiple Myeloma Research and Treatments

Multiple Myeloma Research and Treatments

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Holly Lee
University of Calgary
2
Green Ahn
University of Washington
3
Madelon M.E. de Jong
University of Oxford
4
Saki Ichikawa
Tokyo University of Agriculture
5
Christine Riedhammer
Universitätsklinikum Würzburg
6
Christie P.M. Verkleij
Dutch Cancer Society
7
Nathaniel J. Henning
Berkeley College
8
Edmond R. Watson
Bristol-Myers Squibb (Germany)
9
Mengyang Chang
University of Arizona
10
Satomi Imaide
University of Dundee

Papers

1
Real-world analysis of teclistamab in 123 RRMM patients from Germany
Leukemia|2024
104 cit.
2
Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma
Blood|2024
63 cit.
3
BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms
Blood|2024
61 cit.
4
T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple Myeloma
Clinical Cancer Research|2024
58 cit.
5
Senolysis Enabled by Senescent Cell‐Sensitive Bioorthogonal Tetrazine Ligation
Angewandte Chemie International Edition|2024
45 cit.
6
The cyclimids: Degron-inspired cereblon binders for targeted protein degradation
Cell chemical biology|2024
40 cit.
7
An IL-1β-driven neutrophil–stromal cell axis fosters a BAFF-rich protumor microenvironment in individuals with multiple myeloma
Nature Immunology|2024
38 cit.
8
Selective Elimination of Senescent Cancer Cells by Galacto-Modified PROTACs
Journal of Medicinal Chemistry|2024
33 cit.
9
Senolysis Enabled by Senescent Cell‐Sensitive Bioorthogonal Tetrazine Ligation
Angewandte Chemie|2024
3 cit.
10
Antigen-dependent clonal sweep with sequential or combinatory anti-myeloma T cell engagers
Blood|2025
3 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Jason Tache
New York Oncology Hematology
2
Christina Fitzmaurice
Gundersen Health System
3
Eric S. Fischer
Dana-Farber Cancer Institute
4
Georg Petzold
Montrose Center
5
Xiaobao Yang
Beijing Friendship Hospital
6
Konstantinos Mavrommatis
Bristol-Myers Squibb (Germany)
7
Alexander W. Hird
Paras Hospitals
8
Amit Choudhary
Broad Institute
9
James S. Duncan
Fox Chase Cancer Center
10
Tom Martin
UCSF Helen Diller Family Comprehensive Cancer Center

Papers

1
Momentum Contrastive Voxel-Wise Representation Learning for Semi-supervised Volumetric Medical Image Segmentation
Lecture notes in computer science|2022
125 cit.
2
Proteolysis-targeting chimeras with reduced off-targets
Nature Chemistry|2023
118 cit.
3
The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells
Science Signaling|2022
107 cit.
4
Bootstrapping Semi-supervised Medical Image Segmentation with Anatomical-Aware Contrastive Distillation
Lecture notes in computer science|2023
83 cit.
5
Mining the CRBN target space redefines rules for molecular glue–induced neosubstrate recognition
Science|2025
71 cit.
6
Structures of BIRC6-client complexes provide a mechanism of SMAC-mediated release of caspases
Science|2023
46 cit.
7
Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA
Haematologica|2022
42 cit.
8
Unveiling the hidden interactome of CRBN molecular glues
Nature Communications|2025
42 cit.
9
Development and Applications of Chimera Platforms for Tyrosine Phosphorylation
ACS Central Science|2023
32 cit.
10
Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma
Current Medical Research and Opinion|2022
25 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Kenneth C. Anderson
Dana-Farber Cancer Institute
2
Jesús F. San Miguel
Clinica Universidad de Navarra
3
S. Vincent Rajkumar
WinnMed
4
Bart Barlogie
University of Arkansas for Medical Sciences
5
Philippe Moreau
Centre National de la Recherche Scientifique
6
Paul G. Richardson
Harvard University
7
Gareth J. Morgan
Hywel Dda University Health Board
8
Shaji Kumar
Mayo Clinic
9
Meletios Α. Dimopoulos
Korea University
10
James E. Bradner
Novartis (China)

Papers

1
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
The Lancet Oncology|2014
4.9k cit.
2
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
New England Journal of Medicine|2003
2.6k cit.
3
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
New England Journal of Medicine|1999
2.6k cit.
4
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
New England Journal of Medicine|2005
2.5k cit.
5
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
New England Journal of Medicine|2021
2.4k cit.
6
Improved survival in multiple myeloma and the impact of novel therapies
Blood|2007
2.3k cit.
7
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Journal of Clinical Oncology|2015
2.2k cit.
8
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
New England Journal of Medicine|2008
1.9k cit.
9
Phthalimide conjugation as a strategy for in vivo target protein degradation
Science|2015
1.7k cit.
10
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
New England Journal of Medicine|2007
1.5k cit.

Reagents for Multiple Myeloma Research and Treatments

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 67

CRBN (D8H3S) Rabbit Monoclonal Antibody

Cited in 11 papers
#71810$169,998
View Evidence →
Cell Signaling TechnologyEvidence 67

Aiolos (D1C1E) Rabbit Monoclonal Antibody

Cited in 11 papers
#15103$149,348
View Evidence →
Cell Signaling TechnologyEvidence 65

p44/42 MAPK (Erk1/2) (137F5) Rabbit Monoclonal Antibody (Biotinylated)

Cited in 9 papers
#5013$556
View Evidence →

🌟 All-Time

Most validated

Cell Signaling TechnologyEvidence 67

TIGIT (E5Y1W) Rabbit Monoclonal Antibody (BSA and Azide Free)

Cited in 29 papers
#17046$865
View Evidence →
Cell Signaling TechnologyEvidence 61

HIP2 (D27C4) Rabbit Monoclonal Antibody

Cited in 27 papers
#8226$161,351
View Evidence →
Cell Signaling TechnologyEvidence 68

TPX2 Antibody

Cited in 14 papers
#8559$136,317
View Evidence →